Xiyin Wang, MS
Targeting a Shared Vulnerability in Breast and Ovarian Cancer
Summary
Triple-negative breast cancer and ovarian cancer are challenging to treat because they often become resistant to existing therapies, making recurrence common and survival rates low. My research focuses on a protein called CTPS1 that is essential for these cancer cells to grow and survive. We have identified a new drug that can block this protein, effectively slowing down or stopping the growth of cancer cells. This drug shows promise, especially when used alongside standard treatments, and could lead to new, more effective therapies for patients. Our goal is to bring this drug to clinical trials, providing hope for better treatment options in the future.
Watch a Q&A with Xiyin
I am truly grateful for the support of PhRMA Foundation to advance our technology for developing advanced gene therapy products. It's a recognition of the potential impact my work can have on the field of drug discovery. I am excited about the possibilities it brings for my future endeavors and contributing to innovative and advanced therapeutics to benefit patients.
